A day after seladelpar is canned over toxicity fears elafibranor passes a safety review, but should Genfit holders worry all the same?
A multifaceted tie-up effectively gives Beigene a net $1.5bn fund-raising and several Amgen drugs to sell locally.
Pain drugs look like they could face different outcomes, while targeted cancer agents will have a big month. Two biosimilar decisions also await.
It’s time for Viking, a Nash player that has climbed in tandem with one of its biotech peers, to prove itself.